Larvol Delta - BioPath-Holdings-Announces-First-Patient-Dosed-in-Phase-11b-Clinical-Trial-of-BP1001A-in-Solid-Tumors

prexigebersen-A (BP1001-A) - Bio-Path

https://www.globenewswire.com/news-release/2022/12/07/2569142/0/en/Bio-Path-Holdings-Announces-First-Patient-Dosed-in-Phase-1-1b-Clinical-Trial-of-BP1001-A-in-Solid-Tumors.html

Dec 7, 2022

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next